Can FDA-Approved Lipfendra Help Lower LDL Cholesterol?

The US FDA has approved Lipfendra, the first pill that blocks the PCSK9 protein to lower bad (LDL) cholesterol. It cut LDL cholesterol by up to 59% in clinical trials.

The US Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) as the first oral medicine that blocks the PCSK9 protein to lower low-density lipoprotein cholesterol (LDL-C), commonly known as “bad” cholesterol (1^✔ ✔Trusted Source
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

Go to source

).
The drug is approved as an add-on to diet and exercise for adults with hypercholesterolemia, including people with heterozygous familial hypercholesterolemia (HeFH), an inherited disorder that causes very high cholesterol levels.

Until now, medicines targeting PCSK9 were available only as injections. Lipfendra changes that by offering a once-daily tablet, giving patients and doctors another treatment option when LDL cholesterol remains high despite statins or other cholesterol-lowering medicines.

Why Is Lipfendra’s FDA Approval Important?

Several medicines are already available to lower LDL cholesterol, including statins, ezetimibe, and injectable PCSK9 inhibitors.

However, according to the FDA, many patients continue to have cholesterol levels above recommended targets even after receiving these treatments.

Lipfendra is the first oral medicine that directly blocks the PCSK9 protein, making this treatment approach more convenient for people who may prefer tablets over injections.

The FDA based its approval on two international Phase 3 clinical trials involving 3,207 adults receiving maximally tolerated statin therapy.

Participants taking Lipfendra achieved average LDL cholesterol reductions of 56% and 59% after 24 weeks compared with placebo.

Further evidence came from the Phase 3 CORALreef AddOn trial, published in the Journal of the American College of Cardiology (JACC) (2^✔ ✔Trusted Source
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial

Go to source).

Researchers found that Lipfendra lowered LDL cholesterol significantly more than ezetimibe, bempedoic acid, or the combination of both medicines when added to statin therapy.

The study also showed greater reductions in apolipoprotein B (ApoB) and non-HDL cholesterol, two important markers of cardiovascular risk.

These findings suggest that the new oral medicine could help more patients achieve recommended cholesterol targets without needing injectable therapy.

What Is PCSK9 and How Does It Affect Cholesterol?

To understand why Lipfendra is different, it helps to know the role of a protein called PCSK9.

The liver continuously removes LDL cholesterol from the bloodstream using LDL receptors present on liver cells. These receptors capture LDL particles, move them into the liver, and then return to the cell surface to collect more cholesterol (3^✔ ✔Trusted Source
What Is PCSK9 and How Does It Affect Cholesterol?

Go to source).

PCSK9 interrupts this natural recycling process.

When the protein attaches to an LDL receptor, both are destroyed inside the liver cell instead of being recycled.

As fewer LDL receptors remain on the liver surface, less LDL cholesterol is removed from the bloodstream. Over time, cholesterol levels rise, increasing the risk of plaque formation, heart attack, and stroke.

Researchers first discovered the importance of PCSK9 by studying people born with naturally inactive versions of the gene.

These individuals consistently had much lower LDL cholesterol and a substantially lower lifetime risk of coronary heart disease. This discovery eventually led to the development of medicines that block the PCSK9 protein.

Lipfendra works by preventing PCSK9 from binding to LDL receptors. As more receptors survive, the liver can remove larger amounts of LDL cholesterol from the blood, leading to significant cholesterol reduction.

How Is Lipfendra Different from Statins?

Statins are the first-choice treatment for high cholesterol, but many people still do not reach their target LDL cholesterol levels. Lipfendra works differently by helping the liver remove more LDL cholesterol from the blood, making it a useful add-on to statin therapy.

In the Phase 3 CORALreef AddOn study published in JACC, Lipfendra lowered LDL cholesterol, ApoB, and non-HDL cholesterol more than commonly used oral non-statin medicines. Researchers say this could benefit people who need greater LDL reduction.

Here’s how Lipfendra compares with other commonly used cholesterol-lowering medicines.

Comparison of Lipfendra and Other Cholesterol-Lowering Medicines

Who May Benefit from Lipfendra?

According to the FDA prescribing information, Lipfendra is approved as an add-on to diet and exercise for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia.

Doctors may consider the medicine for people who:

• Have persistently high LDL cholesterol despite taking statins.
• Cannot reach recommended cholesterol targets with current treatment.
• Need additional LDL lowering because of very high cardiovascular risk.
• Have inherited forms of high cholesterol such as HeFH.

The medicine is not intended to replace healthy eating, exercise, weight management, or statin therapy. Instead, it is designed to work alongside these measures to provide additional cholesterol reduction.

Researchers also continue to study whether long-term treatment with Lipfendra reduces heart attacks, strokes, and cardiovascular deaths. Those outcome studies are still ongoing.

How Should Lipfendra Be Taken and What Are Its Side Effects?

The recommended dose of Lipfendra is 20 mg once daily. The tablet should be swallowed whole with water and can be taken with or without food (4^✔ ✔Trusted Source
HIGHLIGHTS OF PRESCRIBING INFORMATION

Go to source

).

As Lipfendra is a peptide medicine, patients should avoid eating, drinking, or taking other oral medicines for at least 30 minutes after taking the tablet. This helps the body absorb the medicine properly. If a dose is missed, patients should follow their doctor’s advice and should not double the next dose.

The FDA reported that Lipfendra was generally well tolerated during clinical trials. The most common side effects were diarrhea, itching, pain in the arms or legs, and urinary tract infection. Most of these were mild to moderate.

As the medicine is newly approved, its long-term safety will continue to be monitored through ongoing studies and post-marketing surveillance. Patients should seek medical attention immediately if they develop signs of an allergic reaction or any severe or unexpected side effects.

How Could Lipfendra Benefit Indian Patients?

Although Lipfendra has been approved in the United States, the need for better cholesterol control is equally relevant for India.

According to a review published in the Indian Heart Journal, dyslipidemia remains one of the leading contributors to coronary artery disease in the country. The review highlights that cholesterol abnormalities continue to rise across India, with considerable regional differences.

Data from the nationwide ICMR-INDIAB study showed that around 24% of Indian adults have hypercholesterolemia, 20.9% have high LDL cholesterol, nearly 67% have low HDL cholesterol, and more than 32% have elevated triglycerides (5^✔ ✔Trusted Source
Trends in epidemiology of dyslipidemias in India

Go to source).

Although Lipfendra is not yet available in India, advances like this highlight the growing focus on improving cholesterol management worldwide. Combined with healthy lifestyle habits, effective LDL-lowering treatment can help protect long-term heart health.

References:

1. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol – (https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol)
2. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial – (https://www.jacc.org/doi/10.1016/j.jacc.2026.03.036)
3. What Is PCSK9 and How Does It Affect Cholesterol? – (https://scienceinsights.org/what-is-pcsk9-and-how-does-it-affect-cholesterol/)
4. HIGHLIGHTS OF PRESCRIBING INFORMATION – (https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf)
5. Trends in epidemiology of dyslipidemias in India – (https://www.sciencedirect.com/science/article/pii/S0019483223004571)

Source-Medindia